Chronic Hepatitis E in a Heart Transplant Patient: Sofosbuvir and Ribavirin Regimen Not Fully Effective - Sorbonne Université Access content directly
Journal Articles Antiviral therapy Year : 2018

Chronic Hepatitis E in a Heart Transplant Patient: Sofosbuvir and Ribavirin Regimen Not Fully Effective

Abstract

Hepatitis E virus (HEV) can induce chronic infections in the case of immunosuppression, which are sometimes not cured with ribavirin. Furthermore, sofosbuvir is a highly potent inhibitor of HCV polymerase and was shown to inhibit HEV genotype-3 replication in vitro. We report here the outcome of sofosbuvir/ribavirin therapy on a chronic HEV infection in a heart transplant recipient non-responder to ribavirin. After 24 weeks, the regimen failed to cure the persistent HEV infection, highlighting the need of therapeutic options for HEV-infected immunosuppressed patients.
No file

Dates and versions

hal-03793547 , version 1 (01-10-2022)

Identifiers

Cite

Eve Todesco, Alessandra Mazzola, Sepideh Akhavan, Florence Abravanel, Thierry Poynard, et al.. Chronic Hepatitis E in a Heart Transplant Patient: Sofosbuvir and Ribavirin Regimen Not Fully Effective. Antiviral therapy, 2018, 23 (5), pp.463--465. ⟨10.3851/IMP3227⟩. ⟨hal-03793547⟩
35 View
0 Download

Altmetric

Share

Gmail Mastodon Facebook X LinkedIn More